Zoledronic acid
- Generic Name
- Zoledronic acid
- Brand Names
- Aclasta, Reclast, Zometa, Zoledronic Acid Accord, Zoledronic acid Actavis, Zoledronic acid medac, Zoledronic acid Teva, Zoledronic Acid Hospira, Zoledronic acid Mylan
- Drug Type
- Small Molecule
- Chemical Formula
- C5H10N2O7P2
- CAS Number
- 118072-93-8
- Unique Ingredient Identifier
- 70HZ18PH24
- Background
Zoledronic acid, or CGP 42'446, is a third generation, nitrogen containing bisphosphonate similar to ibandronic acid, minodronic acid, and risedronic acid. Zoledronic acid is used to treat and prevent multiple forms of osteoporosis, hypercalcemia of malignancy, multiple myeloma, bone metastases from solid tumors, and Paget’s disease of bone. Zoledronic acid ...
- Indication
Zoledronic acid is indicated to treat hypercalcemia of malignancy, multiple myeloma, bone metastases from solid tumors, osteoporosis in men and postmenopausal women, glucocorticoid induced osteoporosis, and Paget's disease of bone in men and women. Zoledronic acid is also indicated for the prevention of osteoporosis in post menopausal women and glucocorticoi...
- Associated Conditions
- Bone Metastases, Hypercalcemia of Malignancy, Multiple Myeloma (MM), Osteoporosis, Osteoporosis caused by Glucocorticoid Treatment, Paget's Disease of Bone, Paget’s Disease
- Associated Therapies
- Bone Mineral Density
Zoledronic Acid in Decrease the Lung Metastatic Rate of Osteosarcoma
- First Posted Date
- 2019-04-30
- Last Posted Date
- 2019-05-06
- Target Recruit Count
- 150
- Registration Number
- NCT03932071
- Locations
- 🇨🇳
2nd Affiliated Hospital of Zhejiang University, Hangzhou, Zhejiang, China
Denosumab Sequential Therapy
- First Posted Date
- 2019-03-08
- Last Posted Date
- 2024-04-23
- Lead Sponsor
- National Taiwan University Hospital
- Target Recruit Count
- 101
- Registration Number
- NCT03868033
- Locations
- 🇨🇳
Department of Orthopedics, National Taiwan University Hospital, Taipei, N/A = Not Applicable, Taiwan
Zoledronic Acid in Combination With Interleukin-2 to Expand Vγ9Vδ2 T Cells After T-replete Haplo-identical Allotransplant
- Conditions
- Interventions
- First Posted Date
- 2019-03-05
- Last Posted Date
- 2023-10-06
- Lead Sponsor
- Nantes University Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT03862833
- Locations
- 🇫🇷
Nantes Uh, Nantes, France
Treatment of Osteogenesis Imperfecta With Parathyroid Hormone and Zoledronic Acid
- Conditions
- Interventions
- First Posted Date
- 2018-11-08
- Last Posted Date
- 2022-03-16
- Lead Sponsor
- University of Edinburgh
- Target Recruit Count
- 380
- Registration Number
- NCT03735537
- Locations
- 🇬🇧
Bristol Royal Infirmary, Bristol, United Kingdom
🇮🇪St Vincent's Hospital, Dublin, Ireland
🇬🇧Aberdeen Royal Infirmary, Aberdeen, United Kingdom
Comparing a Single-Dose vs. Twice Yearly Zoledronate in Patients With Early Stage Breast Cancer (REaCT-ZOL)
- First Posted Date
- 2018-09-10
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Ottawa Hospital Research Institute
- Target Recruit Count
- 211
- Registration Number
- NCT03664687
- Locations
- 🇨🇦
Ottawa Hospital Research Institute, Ottawa, Ontario, Canada
Pilot Study for Zoledronic Acid to Prevent Bone Loss After Bariatric Surgery
- Conditions
- Interventions
- First Posted Date
- 2018-02-06
- Last Posted Date
- 2021-04-29
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 6
- Registration Number
- NCT03424239
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
Bisphosphonates for Prevention of Post-Denosumab Bone Loss
- First Posted Date
- 2018-01-10
- Last Posted Date
- 2024-05-08
- Lead Sponsor
- Columbia University
- Target Recruit Count
- 24
- Registration Number
- NCT03396315
- Locations
- 🇺🇸
Columbia University Medical Center, New York, New York, United States
🇺🇸Creighton University, Omaha, Nebraska, United States
Neoadjuvant Zoledronate and Atorvastatin in Triple Negative Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2017-11-30
- Last Posted Date
- 2023-10-19
- Target Recruit Count
- 54
- Registration Number
- NCT03358017
- Locations
- 🇮🇹
Azienda Socio Sanitaria Territoriale ASST Monza - Ospedale S. Gerardo, Monza, Italy
🇮🇹Azienda Socio Sanitaria Territoriale ASST Lariana - Presidio Ospedaliero Ospedale S. Anna, San Fermo della Battaglia, Como, Italy
🇮🇹Azienda Socio Sanitaria Territoriale - ASST Papa Giovanni XXIII, Bergamo, Italy
Luteinizing Hormone-releasing Hormone Analogue and Enzalutamide +/- Zoledronic Acid in Prostate Cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2017-11-08
- Last Posted Date
- 2024-08-01
- Target Recruit Count
- 126
- Registration Number
- NCT03336983
- Locations
- 🇮🇹
Azienda Ospedaliera Spedali Civili di Brescia, Brescia, Italy
Efficacy of Zoledronic Acid in Osteoporosis of Children With Multiple Disabilities
- First Posted Date
- 2017-10-04
- Last Posted Date
- 2017-10-04
- Lead Sponsor
- Central Hospital, Nancy, France
- Target Recruit Count
- 60
- Registration Number
- NCT03301285
- Locations
- 🇫🇷
Children's Hospital - CHRU de Nancy, Vandoeuvre les nancy, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.